Stay updated with breaking news from Anthonym Hunter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Anthony M. Hunter, MD, discusses the evolution of JAK inhibitors in myelofibrosis, a topic that was highlighted in a presentation at the 2023 SOHO Annual Meeting.
Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.
"We are thankfully starting to be blessed with more options than we've ever had," but "in the frontline proliferative setting, ruxolitinib has remained the standard of care."
Anthony M Hunter, MD, discusses the current treatment landscape with JAK inhibitors in myelofibrosis.